comprehensive -WSS

comprehensive

author：fashion 2025-08-26 03:42:23 - browse：5

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Trump surgeon general acknowledges mistakes during Covid

leisure time

WSS

Humana sues Biden admin over Medicare Advantage audit rule

Medicare bonuses could stop drug shortages under Senate plan

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Crinetics acromegaly drug succeeds in late

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Medicaid rebukes states for mistakenly disenrolling children

focus

comprehensive

Wikipedia

What does generative AI mean for health care? We asked experts

Immunocompromised patients offer clues on chronic Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What American doctors can learn from their Israeli counterparts

Drug repurposing or repositioning? The language matters

Dog Aging Project founders on what lies ahead after losing funding

In age of alternative facts, a scholarly course on calling out crap

Mass General, Mayo Clinic look to monetize custom

In Memoriam: Notable people who died in 2023

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Wikipedia

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Medicare bonuses could stop drug shortages under Senate plan

Trump surgeon general acknowledges mistakes during Covid

Inaction leaves children at risk from dangerous chemotherapy drug

A pediatrician calls for Congress to pass the child tax credit deal

Crinetics acromegaly drug succeeds in late

leisure time

knowledge

leisure time

leisure time